UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
SAN DIEGO, Feb. 28, 2018 -- Retrophin, Inc. (NASDAQ:RTRX) today announced that Stephen Aselage, chief executive officer, will present at the Barclays Global Healthcare Conference in Miami on Wednesday, March 14, 2018 at 3:50 p.m. ET.
A live webcast of the presentation will be available at ir.retrophin.com/events and an archived replay will be accessible for up to 30 days.
About Retrophin
Retrophin is a biopharmaceutical company specializing in identifying, developing and delivering life-changing therapies to people living with rare diseases. The Company’s approach centers on its pipeline featuring late-stage assets targeting rare diseases with significant unmet medical needs, including fosmetpantotenate for pantothenate kinase-associated neurodegeneration (PKAN), a life-threatening neurological disorder that typically begins in early childhood, and sparsentan for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN), disorders characterized by progressive scarring of the kidney often leading to end-stage renal disease and glomerulonephritis, respectively. Research in additional rare diseases is also underway, including a joint development arrangement evaluating the potential of CNSA-001 in phenylketonuria (PKU), a rare genetic metabolic condition that can lead to neurological and behavioral impairment. Retrophin’s R&D efforts are supported by revenues from the Company’s commercial products Chenodal®, Cholbam® and Thiola®.
Contact:
Chris Cline, CFA
Vice President, Investor Relations & Corporate Communications
760-260-8600
[email protected]
